U.S., Jan. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07364357) titled 'A Phase I Study of CREPT-618 in Locally Advanced HCC' on Sept. 16, 2025.
Brief Summary: This is a single-center, open-label, dose-escalation Phase I clinical study designed to evaluate the safety (incidence of adverse events), maximum tolerated dose (MTD), optimal biological dose (OBD), and recommended Phase II dose (RP2D) of CREPT-618 in adult patients aged 18-75 with locally advanced hepatocellular carcinoma who have failed standard treatment.
The study adopts a 3+3 dose escalation design for dose climbing, primarily consisting of three dose groups: low dose, medium dose, and high dose. Patient enrollment and dose escalation in e...